PTC THERAPEUTICS, INC.
PTC Therapeutics is a global biopharmaceutical company that discovers, develops and commercializes medicines for children and adults with rare disorders. Its commercial products include Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza and Kebilidi for AADC deficiency, and Evrysdi for spinal muscular atrophy. PTC also holds rights to commercialize Tegsedi and Waylivra for rare diseases in Latin America and the Caribbean. Evrysdi is developed through a collaboration with Roche and the SMA Foundation; PTC collaborates with Novartis on votoplam, a Huntington’s disease program. PTC’s development and discovery work includes splicing and inflammation and ferroptosis platforms, with programs such as votoplam and vatiquinone, as well as pre-clinical research. It makes money by commercializing its medicines and by licensing and collaboration arrangements. PTC Therapeutics is headquartered in Warren, New Jersey.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
PTC Therapeutics reported Q3 GAAP EPS of -$0.62, missing estimates by $0.76, but revenue of $358M exceeded expectations by $52.99M, up 69.7% year-over-year. The company raised its full-year revenue guidance to $1.29B-$1.32B, above the consensus of $1.26B.
Truist resumed coverage of PTC Therapeutics (PTCT) with a Hold rating and $62 price target, citing limited growth prospects for its drug Sephience. PTCT trades at a P/S ratio of 5.22x, below its historical median, and has a GF Score of 59/100. Insiders sold $53.9M in shares over the past year. The company focuses on rare disorder treatments and has a $5.09B market cap.
PTC Therapeutics (PTCT) will report its Q3 2026 financial results and provide a business update on Oct. 29, 2026, via a webcast and conference call. The company focuses on developing treatments for rare disorders and has a diversified pipeline of medicines.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning PTCT (PTC THERAPEUTICS, INC.). Coverage has skewed bullish: 8 bullish, 1 neutral, and 0 bearish.
Recent PTCT coverage spans financial news, earnings and insider activity.
In the last 30 days, PTCT insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($1.2M). The most active reporter was SCHMERTZLER MICHAEL with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Beat on revenue and raised full-year guidance should support the stock, but the GAAP EPS miss may cap upside until investors focus on profitability trajectory.
Analyst downgrade and modest price target suggest potential downside pressure.
Near-term positioning may shift ahead of the Oct. 29 earnings release as traders anticipate the quarter’s results and business update.
Small insider sale may cause modest short‑term selling pressure.
Insider sale may signal confidence concerns and could weigh on the stock.
AlphAI scores every news story that mentions PTCT with an AI model for sentiment and relevance, and aggregates insider trades from PTC THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PTC Therapeutics reported Q3 GAAP EPS of -$0.62, missing estimates by $0.76, but revenue of $358M exceeded expectations by $52.99M, up 69.7% year-over-year. The company raised its full-year revenue guidance to $1.29B-$1.32B, above the consensus of $1.26B.
2 min readTruist resumed coverage of PTC Therapeutics (PTCT) with a Hold rating and $62 price target, citing limited growth prospects for its drug Sephience. PTCT trades at a P/S ratio of 5.22x, below its historical median, and has a GF Score of 59/100. Insiders sold $53.9M in shares over the past year. The company focuses on rare disorder treatments and has a $5.09B market cap.
2 min readPTC Therapeutics (PTCT) will report its Q3 2026 financial results and provide a business update on Oct. 29, 2026, via a webcast and conference call. The company focuses on developing treatments for rare disorders and has a diversified pipeline of medicines.
2 min readPTC Therapeutics' CLO Mark Boulding sold 192 shares for $12,337 and acquired 192 shares via options. PTCT shares trade near 52-week lows, down 21% YTD. Q2 2026 earnings beat estimates, with revenue at $361M. Analysts raised price targets post-acquisition of ST-920 gene therapy. InvestingPro lists PTCT as undervalued.
1 min readPTC Therapeutics director Michael Schmertzler sold $158,480 in shares indirectly through Section Six Partners, L.P. The shares were sold at $63.38 to $63.95 each, with PTCT stock currently at $64.70. The company, with a $5.37B market cap, reports earnings on October 22. Analysts' price targets range from $70 to $137. PTCT reported Q2 2026 earnings of $0.92 per share on $361M revenue, exceeding expectations.
1 min readArgus lowered its target price for PTC Therapeutics (PTCT) to $61.00, maintaining a HOLD rating. The company has medium ratings for industry, management, and growth, but low ratings for safety and value.
1 min readRBC Capital reiterated its Sector Perform rating on PTC Therapeutics (PTCT) with an $85 price target, citing its strong balance sheet and early-stage pipeline. The company's Q2 2026 earnings of $0.92 per share on $361M revenue beat estimates. PTCT completed a gene therapy acquisition and raised its full-year outlook. Cantor Fitzgerald raised its price target to $137, maintaining an Overweight rating.
2 min readSTEELE GLENN JR MD PHD sold 12,000 shares of PTC THERAPEUTICS, INC. (PTCT) at $65.16 ($0.78M total) on 2026-09-30 under a Rule 10b5-1 trading plan.
1 min readCantor Fitzgerald kept its Overweight rating on PTC Therapeutics (PTCT) with a $137 price target, implying a 109.9% upside from the Sep 21 close. The firm cited PTC's acquisition of ST-920 for Fabry disease and the growing recognition of its pipeline value as reasons for the rating.
1 min readPTC THERAPEUTICS, INC. (PTCT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo
2 min read
